Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients
Why the study?
Anthracyclines carry a significant risk of cardiotoxicity and overt heart failure, creating a need for effective preventive strategies as cancer survival improves.
Do lifestyle and pharmacological interventions prevent anthracycline-related cardiotoxicity in cancer patients?
Population
Cancer patients receiving anthracyclines
Comparison
Lifestyle and pharmacological preventive interventions
Design
Narrative review
Authors
Discussion
Loading...
Member takes
Implication
May support integrated cardio-oncology prevention; leaves open confirmation in prospective randomized trials.
Structured PICO
Do lifestyle and pharmacological interventions prevent anthracycline-related cardiotoxicity in cancer patients?
P
Population
Cancer patients receiving anthracyclines
I
Intervention
Lifestyle modifications (structured exercise programs, antioxidant-rich diets) and pharmacological interventions (beta-blockers, renin-angiotensin system inhibitors, dexrazoxane, SGLT2 inhibitors, sacubitril/valsartan)
O
Outcome
Anthracycline-induced cardiotoxicity
A multidisciplinary cardio-oncology approach integrating lifestyle and pharmacological strategies may provide optimal protection against anthracycline-induced cardiotoxicity.
Cite This Study
Spadafora et al. (2025) studied this question.